Important Milestone Achieved by Anatara Lifesciences in the Human Product Pipeline

Healthcare

Anatara Lifesciences Limited (ASX: ANR) operates in the field of biological sciences. The Company develops non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.

The company has reported the encouraging results of it’s in vitro Proof of Concept (PoC) studies of the Gastrointestinal Reprogramming (GaRP) product. This product is a dietary supplement which helps to restore as well as maintain healthy human digestion. This product focusses on targeting certain specific components in the small intestine, where they have a more significant impact in terms of therapeutic benefits. The company anticipates to start up with its plans to conduct clinical studies for the IBS & the patient recruitment for the same is slated to commence in the 2H 2019. 

The management of the company seems to be very confident from these data & the reviews that it has received from the medical practitioners practicing in the domain of treating disorders of the stomach and intestines. These reviews suggest that this product can prove to be a massive milestone in the dietary product segment & its human product pipeline.

For the quarter ended 31st December 2018, the company had cash of $1.5m on its balance sheet. Also, the company had received a Research and Development (R&D) Tax Incentive of $1,249,299 from the Australian Taxation Office in January 2019. This incentive will prove to be a non-dilutive source for funding the development & commercialization of the GaRP product.

The company has got solid leadership in place now with the appointment of Mr. Steven Lydeamore as Chief Executive Officer (CEO) of the company. Mr. Lydeamore has 26 years’ international experience in the pharmaceutical industry, specializing in the commercialization of products globally which inculcates into sales growth as well as enhancing shareholders value. Also, the company’s board comprises of eminent experts in the domain of human gastrointestinal health.

As regards the operational outlook for the FY 2019, the management expects that it will be wholly focussed towards its new initiatives in the human health specifically in the development of the GaRP dietary supplement which will prove to be phenomenon in the treatment of disorders such as the Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Now, let us have a quick look at Anatara Lifesciences Limited’s stock performance and the return it has posted over the last few months. The stock is currently trading at a price of $0.49, trading down by 2% during the day with a market capitalization of ~$24.71 Million. The counter opened the day at $0.49, which was also the day’s high with a daily volume of 25,824. The stock has provided a YTD return of 11.11% & also posted returns of -18.03%, 4.17% & 11.11% over the past six months, three & one-months period respectively. It had a 52-week high price of $ 1.785 and touched 52 weeks low of $ 0.375, with an average volume of 27,862 approximately.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.